Skip to main content
Signal8
Launch Terminal

ELUTIA INC. (ELUT)

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Elutia Inc logo

Elutia Inc

NASDAQ:ELUTHealthcare
+2.89%$0.8371
AH$0.8371+0.00%vs close
Mkt Cap$37.07M
Float38.06M
O/S44.29M
Vol
$ Vol
RVOL
Inst Own32.6%
SI<0.1%
Earnings
Dilution
Elutia Inc logoNASDAQ:ELUT$0.8371+2.89%
Phase Distribution
14 lead-sponsored trials·1 active·10 completed
Not applicable14
Status Overview
Active, not recruiting1
Completed10
Stopped3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
  • Not applicable
    Completed

    Evaluation Of New Onset Postoperative Atrial Fibrillation

    CorMatrix ECM for Pericardial Closure

    Atrial Fibrillation New Onset

    Enrollment
    439
    Start
    Dec 2010
    Primary Completion
    Dec 2012
    Completion
    Dec 2012
    NCT01247974
  • Observational
    Completed

    CorMatrix ECM for Carotid Repair Following Endarterectomy Registry

    CorMatrix ECM for Carotid Repair

    Carotid Stenosis

    Enrollment
    230
    Start
    Apr 2012
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT01569594
  • Observational
    Completed

    Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)

    -

    Coronary Disease

    Enrollment
    1,420
    Start
    Mar 2014
    Primary Completion
    Dec 2017
    Completion
    Dec 2017
    NCT02073331
  • Observational
    Withdrawn

    A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope

    CorMatrix CanGaroo ECM Envelope

    Coronary Disease

    Enrollment
    0
    Start
    Sep 2015
    Primary Completion
    Jan 2016est.
    Completion
    Feb 2016est.
    NCT02418143
  • Observational
    Completed

    A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction

    CorMatrix ECM for Vascular Repair

    Peripheral Vascular Disease

    Enrollment
    38
    Start
    May 2015
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT02418156
  • Observational
    Completed

    A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope

    -

    Cardiovascular Disease

    Enrollment
    1,025
    Start
    Oct 2015
    Primary Completion
    Dec 2017
    Completion
    Apr 2018
    NCT02530970
  • Observational
    Completed

    ViBone in Cervical and Lumbar Spine Fusion

    ViBone

    Spondylosis, Cervical Spondylosis +3

    Enrollment
    118
    Start
    May 2018
    Primary Completion
    Jan 2021
    Completion
    Jun 2021
    NCT03425682
  • Observational
    Withdrawn

    A Study Evaluating 3-Level OLIF Spine Fusion

    ViBone®, Demineralized Bone Matrix

    Spondylolisthesis, Retrolisthesis +1

    Enrollment
    0
    Start
    Jul 2019
    Primary Completion
    Feb 2020
    Completion
    Feb 2020
    NCT03896347
  • Observational
    Completed

    A Retrospective Breast Reconstruction Study

    SimpliDerm HADM, AlloDerm HADM

    Breast Cancer

    Enrollment
    223
    Start
    Nov 2019
    Primary Completion
    Mar 2022
    Completion
    Jun 2022
    NCT04060134
  • Not applicable
    Withdrawn

    CIED Implantation in Low BMI Patients

    CanGaroo

    Heart Diseases, Cardiac Disease

    Enrollment
    0
    Start
    Jun 2021est.
    Primary Completion
    Dec 2021est.
    Completion
    Mar 2022est.
    NCT04299282
  • Observational
    Completed

    Retrospective Experience Of CIED Implantation

    CanGaroo Envelope, TYRX Envelope

    Cardiac Disease, Heart Failure +1

    Enrollment
    597
    Start
    Apr 2020
    Primary Completion
    Jun 2021
    Completion
    Jun 2021
    NCT04351269
  • Observational
    Completed

    Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED Implantation

    CIED envelope

    Cardiac Disease

    Enrollment
    46
    Start
    Feb 2021
    Primary Completion
    Oct 2023
    Completion
    Dec 2023
    NCT04645173
  • Observational
    Completed

    CanGaroo® Registry Study

    CanGaroo Envelope

    Arrhythmias, Cardiac

    Enrollment
    500
    Start
    May 2021
    Primary Completion
    Apr 2023
    Completion
    Oct 2024
    NCT04846127
  • Observational
    Active, not recruiting

    EluPro Antibiotic-Eluting BioEnvelope Registry

    EluPro Antibiotic-Eluting BioEnvelope

    Cardiac Arrhythmias

    Enrollment
    100
    Start
    Apr 2025
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT06854081
Search ClinicalTrials.gov for “Elutia”